SGN1

DRUG2 trials

Sponsors

Guangzhou Sinogen Pharmaceutical Co., Ltd

Conditions

Advanced Solid Tumor

Phase 1

Study of SGN1 in Patients With Advanced Solid Tumor

RecruitingNCT05038150

Guangzhou Sinogen Pharmaceutical Co., LtdAdvanced Solid Tumor

Start: 2023-01-16End: 2028-08-31Target: 70Updated: 2026-08-27

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

RecruitingNCT05103345

Guangzhou Sinogen Pharmaceutical Co., LtdAdvanced Solid Tumor

Start: 2023-04-19End: 2028-06-30Target: 70Updated: 2026-08-27

Related Papers

Investigating the oncolytic bacteria product SGN1 and its impact on PD-L1 expression, CD8+ T cell infiltration, and synergy with anti-PD-L1 combo in preclinical models of pancreatic adenocarcinoma, hepatocellular cancer, and melanoma.

Journal of Clinical Oncology2025-05-28

Abstract C119: Combining forces: Integrating engineered bacterial therapeutics with targeted therapies for advanced-stage non-small cell lung cancer

Molecular Cancer Therapeutics2023-12-01

Effects of oncolytic bacteria, SGN1, against a broad spectrum of malignancies in pre-clinical and clinical studies.

Journal of Clinical Oncology2023-06-013 citations